Allergan Inc., producers of the Lap-Band gastric band, is lobbying the FDA to allow them to target teenagers as young as 14 years of age as customers for their weight-loss surgeries.

There has been a decline in the first quarter earnings of Allergan Inc. They have slumped down by 5.7% putting the authorities in serious reviewing. The firm however has covered up for the losses and has been able to gain double digit figures from the revenues collected by the sale of medical devices as well as cosmetic medical products.

The jury of Virginia U. S. District Court has ordered the Allergan Inc. to pay $212 million to a man who has claimed that injections of wrinkle-smoothing Botox left him with brain damage. Afterwards, on Thursday, the company has claimed that the 67-years old-man, Douglas M. Ray, was granted with an amount of $12 million as compensatory damages and $200 million as punitive damages.

Allergan Inc. Has paid $157 million to access Map Pharmaceuticals for the promotion of the company’s experimental migraine treatment Levadex. Both the companies will promote the product to US specialists.

Botox maker Allergan seeks to remove the ban on marketing off-label uses for pharmaceuticals.

According to two late stage trials, Botox, which is popular for smoothing out the wrinkles sold by Allergan Inc., effectively reduced the number of headache days for adults suffering from chronic migraines.

The U.S. Food and Drug Administration have approved an injectable eye implant as a treatment for the retinal disease macular edema.

Though there are speculations abound regarding a prospective sale of the Irvine, California-based cosmetic products-specific company Allergan Inc., the CEO David Pyott said in an interview that the company is itself looking for acquisitions!

The first drug that can enhance eyelash growth has got an approval by the FDA. The drug called Latisse will be manufactured and marketed by Allergan.

Latisse, a drug to promote longer, thicker, darker eyelashes got the recommendations of FDA advisory panel for approval. However the FDA panel also recommended further studies to assess Latisse's use in certain groups of patients, such as young patients and people who lost their eyelashes because of chemotherapy.